Literature DB >> 25465828

Plasma vitamin C and risk of hospitalisation with diagnosis of atrial fibrillation in men and women in EPIC-Norfolk prospective study.

Roman Pfister1, Guido Michels2, Johannes Brägelmann3, Stephen J Sharp4, Robert Luben5, Nick J Wareham6, Kay-Tee Khaw7.   

Abstract

BACKGROUND: Fruit and vegetable intake has been associated with lower risk for cardiovascular risk factors and disease. Data on its association with atrial fibrillation are lacking. METHODS AND
RESULTS: We examined the prospective association of plasma vitamin C concentration as a biomarker for fruit and vegetable intake with the risk of hospitalisation with diagnosis of atrial fibrillation in apparently healthy 8,760 men and 10,530 women aged 39-79 participating in the EPIC-study in Norfolk. The hazard ratios of atrial fibrillation comparing each quartile of plasma vitamin C concentration with the lowest were 0.76 (95% CI 0.57-1.00), 0.73 (95% CI 0.55-0.98) and 0.77 (95% CI 0.58-1.01) in women (p for trend 0.05) and 0.81 (95% CI 0.63-1.03), 0.96 (95% CI 0.76-1.22) and 1.01 (95% CI 0.79-1.28) in men (p for trend 0.66) after adjustment for age, smoking, alcohol consumption, physical activity, systolic blood pressure, diabetes, use of blood pressure medication and body-mass index, with a significant gender × vitamin C interaction (p=0.03). Assuming a linear association, a 20 μmol/l increase in plasma vitamin C concentration (1 standard deviation) was associated with a 13% (95% CI 3-22%) relative reduction in risk of atrial fibrillation in women.
CONCLUSION: Plasma vitamin C was inversely associated with the risk of atrial fibrillation in women, but there was no such association in men. Our findings suggest that intake of food rich in vitamin C might be preventive for atrial fibrillation with a significant benefit particularly in women with low baseline intake.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Fruit and vegetables; Plasma vitamin C

Mesh:

Substances:

Year:  2014        PMID: 25465828     DOI: 10.1016/j.ijcard.2014.11.016

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

Review 1.  Extraoral Taste Receptor Discovery: New Light on Ayurvedic Pharmacology.

Authors:  Marilena Gilca; Dorin Dragos
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-31       Impact factor: 2.629

2.  Inflammatory cell infiltration in left atrial appendageal tissues of patients with atrial fibrillation and sinus rhythm.

Authors:  Christopher Hohmann; Roman Pfister; Martin Mollenhauer; Christoph Adler; Jolanta Kozlowski; Andreas Wodarz; Uta Drebber; Jens Wippermann; Guido Michels
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

3.  Identification of key immune-related genes and immune infiltration in atrial fibrillation with valvular heart disease based on bioinformatics analysis.

Authors:  Shuo Li; Zhiyuan Jiang; Xiaoying Chao; Chenyang Jiang; Guoqiang Zhong
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

4.  Analysis of potential genetic biomarkers using machine learning methods and immune infiltration regulatory mechanisms underlying atrial fibrillation.

Authors:  Li-Da Wu; Feng Li; Jia-Yi Chen; Jie Zhang; Ling-Ling Qian; Ru-Xing Wang
Journal:  BMC Med Genomics       Date:  2022-03-19       Impact factor: 3.063

5.  Vitamin C Deficiency Reduces Muscarinic Receptor Coronary Artery Vasoconstriction and Plasma Tetrahydrobiopterin Concentration in Guinea Pigs.

Authors:  Gry Freja Skovsted; Pernille Tveden-Nyborg; Maiken Marie Lindblad; Stine Normann Hansen; Jens Lykkesfeldt
Journal:  Nutrients       Date:  2017-07-03       Impact factor: 5.717

6.  FEV1 and total Cardiovascular mortality and morbidity over an 18 years follow-up Population-Based Prospective EPIC-NORFOLK Study.

Authors:  Siew-Mooi Ching; Yook-Chin Chia; Marleen A H Lentjes; Robert Luben; Nicholas Wareham; Kay-Tee Khaw
Journal:  BMC Public Health       Date:  2019-05-03       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.